# A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma

> **NCT03003039** · PHASE1 · COMPLETED · sponsor: **Nanjing Yoko Biomedical Co., Ltd.** · enrollment: 85 (actual)

## Conditions studied

- B-Cell Lymphoma

## Interventions

- **BIOLOGICAL:** GB241
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT03003039
- **Lead sponsor:** Nanjing Yoko Biomedical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-05
- **Primary completion:** 2019-05-20
- **Final completion:** 2019-05-20
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2021-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03003039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03003039, "A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03003039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*